Nevertheless, the phenotypical and transcriptomic variability among ROS1+ patient-derived cell lines supports the heterogeneous ROS1+ NSCLC patient outcomes in the clinical setting, reinforcing them as valuable experimental models. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.